Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Overview

About this study

This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

At least 5 yrs since their last menses
Follicle Stimulating Hormone (FSH) > 20 IU/L

Exclusion Criteria:

Abnormality in any of the screening laboratory studies
Presence of significant liver or renal disease
Malignancy (including myeloma)
Malabsorption
Diabetes
Hypoparathyroidism
Hyperparathyroidism
Acromegaly
Cushing's syndrome
Hypopituitarism
Severe chronic obstructive pulmonary disease
Undergoing treatment with any medications that affect bone turnover, including the following:
adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr)
anticonvulsant therapy (within the previous year)
pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal)
calcium supplementation of > 1200 mg/d (within the preceding 3 months)
bisphosphonates (within the past 3 yrs)
denosumab
estrogen (E) therapy within the past year
treatment with a selective E receptor modulator within the past year
teriparatide within the past yr
anti-hypertensive therapy
- Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm
- Recent (within the past 6 months) fracture
- Serum 25-hydroxyvitamin D levels of < 20 ng/ml
- Resting blood pressure >140/90 mm Hg or those with hypotension (systolic blood pressure <110 mm Hg), heart rate < 60 bpm
- History of asthma

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Sundeep Khosla, M.D.	Closed for enrollment	Contact information: Tammie Volkman R.N. (507) 538-6023 Volkman.Tammie@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sundeep Khosla, M.D.

Closed for enrollment

Contact information:

Tammie Volkman R.N.

(507) 538-6023

Volkman.Tammie@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials